The global intracranial hemorrhage diagnosis and treatment market size was valued at USD 1,780.10 million in 2022. It is projected to reach USD 3,071.88 million by 2031, growing at a CAGR of 6.25% during the forecast period (2023-2031).
The market for diagnosing and treating cerebral hemorrhages includes a wide range of goods, including pharmaceuticals from many drug classes, including coagulants and anti-hypertensive drugs used to treat the condition. The sourcing, production, and marketing of items affect how efficiently manufacturers run their businesses. The profitability of the market is impacted by ongoing technological developments in diagnostic tools and surgical techniques, rules set by the government, and consumer preferences. The increased frequency of accidents and trauma cases is responsible for expanding the global intracranial hemorrhage diagnosis and treatment market.
Primary brain and CNS cancers come in more than 120 different kinds. The number of patients needing diagnostic and surgical services is predicted to rise as the number of people with brain cancer increases, contributing to the market expansion. According to the National Health Portal, brain and central nervous system tumors in children make up roughly 26% of all cancers in children in India. A vast patient pool needs medicine to survive and lessen the discomfort of aggressive malignancies and brain tumors. For instance, a report titled Cancer Survival by Stage at Diagnosis for England, 2019 noted a 40% survival rate for one year and a 10% for more than five years for all types of malignant brain tumors.
Necessary surgical procedures are performed on patients yearly to treat brain-related diseases, including congenital disabilities, internal bleeding in the brain, blood clots, epidural anomalies, edema, and infections affecting the skull. The surgical difficulties could worsen the treatment by causing bleeding to break out in the cerebroventricular system and lead to bleeding. A brain aneurysm may burst or leak, resulting in brain hemorrhage (hemorrhagic stroke). According to data from the Brain Aneurysm Foundation, 1 in 50 Americans, or around 6.5 million people, have an unruptured brain aneurysm.
WHO estimates that one in ten medical items sold in underdeveloped nations is subpar or fake. They fail to treat diseases and aid in the development of antibiotic resistance, which, according to British researchers, could result in the yearly deaths of up to 10 million people by the year 2050. For instance, a recent poll in the UK, conducted in 2020 by Sapio Research (UK) on behalf of a private company, Incopro Limited (UK), found that nearly one-third (32%) of people who purchased one or more counterfeit drugs experienced a health problem as a result. Therefore, the proliferation of fake medications can limit the market's expansion and profitability. There are hazards associated with surgically removing a blood clot from the brain. A thick layer of healthy cerebral tissue must be removed while the patient is under general anesthesia to access the hematoma that typically consumes deep brain regions. Also, postoperative complications such as infections are frequent in clinical settings, raising death rates and worsening outcomes.
Consumers are becoming more sensitive and knowledgeable about health-related issues today. As a result, businesses are placing a greater emphasis on research and development to develop new technologies and treatments that will give them a competitive advantage. Businesses anticipate new chemical entities and refined products. In the current environment, prominent companies are crucial in altering market trends for detecting and treating cerebral bleeding. Significant businesses are making strategic decisions, concentrating more on acquisition and partnership to increase product portfolio and bolstering science and technology skills globally.
High-income Middle Eastern nations like Saudi Arabia and the UAE are seeing an improvement in their economic outlook, which is anticipated to grow the region's recovery. A sizable amount of funding is being distributed, and health promotion initiatives are coordinated by the Ministry of Health (MoH) and numerous other governmental entities. The population boom significantly impacts the rising need for healthcare facilities.
The global market is segmented by type and diagnosis.
Based on type, the global intracranial hemorrhage diagnosis and treatment market is bifurcated into epidural hematoma, subdural hematoma, intracerebral hemorrhage, and subarachnoid hemorrhage.
The intracerebral hemorrhage segment is the highest contributor to the market and is estimated to grow at a CAGR of 5.85% during the forecast period. Diagnosis and Treatment of global intracranial bleeding, the high prevalence of strokes, and rising expenditures in the healthcare sector are the primary factors driving this market. The market has been divided into categories based on the types of injuries that can occur, subdivided into intracerebral hemorrhage, subarachnoid hemorrhage, epidural hematoma, and subdural hematoma, respectively. Intracerebral hemorrhage is a type of intracranial bleed that takes place in the brain or the ventricles. This type of bleeding is also referred to as cerebral bleeding. A headache, localized weakness, nausea, vomiting, seizures, decreased focus, and neck rigidity are all possible symptoms.
Subarachnoid bleeding, often known as SAH, is a form of stroke that can be life-threatening and is caused when there is bleeding in the surroundings of the brain. SAH may be caused by a ruptured aneurysm, an arteriovenous malformation (AVM), or head trauma. One-third of patients will fully recover, one-third will be left with mental impairment, and one-third will pass away.
Bleeding between the inside of the skull and the brain's outer layer is called an epidural hematoma (EDH). A skull fracture during childhood or adolescence is frequently the root cause of an EDH. In children older than two years old and younger than two years old, the membrane that covers the brain is linked to the skull more firmly than in younger children. As a result, younger people have a higher incidence of this type of bleeding. A lumbar punch or a headache may cause a condition known as subdural blood hematoma, a collection of blood outside of the brain. Increased brain pressure from a subdural hematoma can sometimes be highly hazardous and life-threatening.
Based on the diagnosis, the global market is bifurcated diagnosis and treatment.
The diagnosis segment is the highest contributor to the market and is estimated to grow at a CAGR of 5.75%during the forecast period. Magnetic resonance imaging (MRI), computed tomography (CT), and other techniques have been included in the diagnosis segment. Brain hemorrhage disease is diagnosed through radiology testing, such as a CT or an MRI scan. These tests demonstrate the various traits and locations of a brain hemorrhage. The nature and location of the hemorrhage in the brain will determine the treatment.
The medicine (anti-hypertensive drug, coagulants, and others) and surgical therapy segments have been added to the treatment section (decompression surgery, craniotomy with open surgery, simple aspiration, endoscopic evacuation, stereotactic aspiration, clipping or coiling procedures). The rise in the prevalence of various types of bleeding on the hemorrhage market and the development of new, highly effective drugs with fewer side effects. In addition, it is projected that the growth of the worldwide hemorrhage treatment market will increase the incidence of severe injuries and the number of patients with high blood pressure.
Along with increased population life expectancy, it is also projected that the expansion of the market will generate a significant need for effective and safe pharmaceuticals. In addition, technological developments, such as point-of-care pharmaceuticals, and a greater emphasis on guaranteeing a higher standard of living, all contribute to the expansion of this sector.
The global intracranial hemorrhage diagnosis and treatment market is bifurcated into four regions: North America, Europe, Asia-Pacific, and LAMEA.
North America is the major revenue contributor and is expected to grow at a CAGR of 6.10% during the forecast period. Aside from research funding, the region has a higher prevalence of patients with different illnesses, including aneurysms. The major manufacturers are projected to introduce new products, work together to improve the cash flow channel, and partially outsource the production process. Additionally, it is launched that integrating clinical data to comprehend the prognosis of cerebral bleeding and therapeutic alternatives will fuel the research activity in the area. The 2019 Brain, CT Hemorrhage Challenge from The Radiological Society of North America (RSNA) aims to develop a machine-learning dataset through a suitable method.
Europe is expected to grow at a CAGR of 5.85% during the forecast period. Europe is expected to experience a significant increase during the predicted period since there are more patients and diagnostic and treatment facilities there. The region's cerebral hemorrhage diagnostic and treatment market is expanding due to the availability of cutting-edge treatment facilities, rising government initiatives to support research to find a cure for the rising number of trauma cases, and increasing healthcare expenditure. According to a study in the U.K. in 2016, intracerebral hemorrhage (ICH), which results from spontaneous bleeding into the brain parenchyma, accounts for 12% of strokes in Western populations and 10-15% of strokes overall.
Asia-Pacific is anticipated to proliferate in the cerebral hemorrhage diagnosis and treatment market. This rapid rise is mainly related to the rising R&D spending for the construction of healthcare infrastructure in developing nations like China and India. Growing rates of traumatic brain injuries in the area due to trauma and accidents are just one of many factors affecting the market's expansion. The market in this region is expanding due to rising demand for cutting-edge medicines, government initiatives, and growing public knowledge of the numerous problems associated with a brain bleed and the range of possible treatments.
In the Middle East and Africa, due to the growing number of businesses and subsidiaries offering treatment options throughout, the market for cerebral hemorrhage is expanding at a rapid rate. In addition to clinical trials, the availability of research grants will likely encourage more researchers to start studies in the area. For instance, the International Brain Research Organization (IBRO) Return Home Fellowships 2021 program offers grants of up to 20,000 Euro to young scientists from underdeveloped nations who have studied neuroscience in world-class research facilities and wish to continue their brain research in their native Africa.
|Report Coverage||Revenue Forecast, Competitive Landscape, Growth Factors, Environment & Regulatory Landscape and Trends|